Uni-Bio Science Group Limited (HKG:0690)
0.0730
0.00 (0.00%)
Sep 21, 2026, 11:25 AM HKT
Uni-Bio Science Group Revenue
Uni-Bio Science Group had revenue of 273.78M HKD in the half year ending June 30, 2026, with 0.06% growth. This brings the company's revenue in the last twelve months to 549.77M, down -6.75% year-over-year. In the year 2025, Uni-Bio Science Group had annual revenue of 586.21M with 6.01% growth.
Revenue (ttm)
549.77M
Revenue Growth
-6.75%
P/S Ratio
0.79
Revenue / Employee
967.90K
Employees
568
Market Cap
435.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 586.21M | 33.23M | 6.01% |
| Dec 31, 2024 | 552.98M | 68.26M | 14.08% |
| Dec 31, 2023 | 484.72M | 44.40M | 10.08% |
| Dec 31, 2022 | 440.32M | 86.91M | 24.59% |
| Dec 31, 2021 | 353.41M | 144.63M | 69.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| 3D Medicines | 412.66M |
| Cutia Therapeutics | 383.95M |
| JW (Cayman) Therapeutics Co. | 333.25M |
| Kintor Pharmaceutical | 90.90M |
| Wuhan YZY Biopharma | 72.52M |
| Shanghai Bio-heart Biological Technology | 44.39M |
| Brii Biosciences | 40.23M |
| Transcenta Holding | 32.70M |
Uni-Bio Science Group News
- 25 days ago - Uni-Bio Science Group Reports Revenue Decline As Biopharmaceutical Pipeline Advances - Nasdaq
- 1 year ago - Uni-Bio Science Secures Approval for Recombinant Collagen Class II Medical Device and Launches : Pioneering Entry into the High-Growth Medical Aesthetics Market - Zawya